Attached files
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended February 28, 2014
OR
[ ]
TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from __________ to ______________
Commission File Number 333-133347
PEPTIDE TECHNOLOGIES, INC.
---------------------------------------------------
(Exact name of registrant as specified in its charter)
Nevada 98-0479983
-------------------------------- --------------------
State or other jurisdiction of (I.R.S. Employer
incorporation or organization Identification No.)
601 Union Street, Two Union Square, 42nd Floor, Seattle, Washington 98101
-------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (206) 236-9555
Indicate by check mark whether the registrant (1) filed all reports required to
be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the past 12 months (or for such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements for
the past 90 days.
Yes [X] No
Indicate by check mark whether the registrant has submitted electronically and
posted on its corporate Web site, if any, every Interactive Data File required
to be submitted and posted pursuant to Rule 405 of Regulation S-T (ss.232.405 of
this chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit and post such files). Yes No [X]
Indicate by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting company. See
definition of "large accelerated filer," "accelerated filer" and "smaller
reporting company" in Rule 12b-2 of the Exchange Act.
Larger accelerated filer [ ] Accelerated filer [ ]
Non-accelerated filer [ ] Smaller reporting company [X]
1
Indicate by check mark whether registrant is a shell company (as defined in Rule
12b-2 of the Exchange Act).
Yes No [X]
Number of shares issued and outstanding of the registrant's class of common
stock as of April 8, 2014: 151,158,000 shares of common stock
The Company recognized $nil revenues during the quarter ended February 28, 2014.
2
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements (Unaudited) Page
----
Consolidated Interim Balance Sheets F-6
Consolidated Interim Statements of Loss and Comprehensive Loss F-7
Consolidated Interim Statements of Cash Flows F-8
Consolidated Interim Statement of Changes in Stockholders' Deficiency F-9
Notes to Interim Financial Statements F-10 to F-24
Item 2. Management's Discussion and Analysis or Plan of Operations 25
Item 3 Quantitative and Qualitative Disclosure about Market Risk 35
Item 4 Controls and Procedures 35-36
PART II - OTHER INFORMATION
Item 1 Legal Proceedings 36
Item 1A. Risk Factors - Not Applicable
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 36
Item 3. Defaults upon Senior Securities - Not Applicable 36
Item 4. Mine Safety Disclosures - Not Applicable 36
Item 5. Other Information 36
Item 6. Exhibits 36
SIGNATURES 37
3
PART I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
PEPTIDE TECHNOLOGIES, INC.
(A Development Stage Company)
INTERIM FINANCIAL STATEMENTS
(Expressed in U.S. Dollars)
(Unaudited)
FEBRUARY 28, 2014
Financial Statements
Page
Interim Consolidated Balance Sheets F-6
Interim Consolidated Statements of Loss and Comprehensive Loss F-7
Interim Consolidated Statements of Cash Flows F-8
Interim Consolidated Statement of Changes in Stockholders' Deficiency F-9
Notes to Interim Consolidated Financial Statements F-10 to F-24
F-4
Peptide Technologies, Inc.
(A Development Stage Company)
Interim Consolidated Financial Statements
(Expressed in U.S. dollars)
(Unaudited)
28 February 2014
F-5
Peptide Technologies, Inc.
(A Development Stage Company)
Interim Consolidated Balance Sheets
(Unaudited)
------------------------------------------------------------------------------------------------------------------
(Expressed in U.S. dollars)
As at 30
As at 28 November 2013
February 2014 (Audited)
Notes $ $
-------------------------------------------------------------------- ---------- ---------------- ------------------
ASSETS
Current assets
Cash and cash equivalents 868 157
Intangible assets and intellectual property 7 45,000 45,000
Website 3 5,000 5,833
-------------------------------------------------------------------- ---------- ---------------- ------------------
Total assets 50,868 50,990
-------------------------------------------------------------------- ---------- ---------------- ------------------
STOCKHOLDERS' DEFICIENCY AND LIABILITIES
Current liabilities
Accounts payable and accrued liabilities 4, 6 1,826,692 1,662,272
Notes payable 5 86,025 88,850
-------------------------------------------------------------------- ---------- ---------------- ------------------
Total liabilities 1,912,717 1,751,122
-------------------------------------------------------------------- ---------- ---------------- ------------------
Stockholders' deficiency
Capital stock 8
Authorized:
675,000,000 common shares, par value $0.001
Issued and outstanding:
28 February 2014 - 151,133,000 common shares
30 November 2013 - 151,123,000 common shares 151,133 151,123
Additional paid-in capital 158,269 148,279
Accumulated deficit (105,837) (105,837)
Accumulated deficit during development stage (2,065,414) (1,893,697)
-------------------------------------------------------------------- ---------- ---------------- ------------------
Total stockholders' deficiency (1,861,849) (1,700,132)
-------------------------------------------------------------------- ---------- ---------------- ------------------
Total stockholders' deficiency and liabilities 50,868 50,990
-------------------------------------------------------------------- ---------- ---------------- ------------------
Nature and Continuance of Operations (Note 1), Commitments and Contingency (Note 11) and Subsequent Events (Note
13)
The accompanying notes are an integral part of these interim consolidated financial statements.
F-6
Peptide Technologies, Inc.
(A Development Stage Company)
Interim Consolidated Statements of Loss and Comprehensive Loss
(Unaudited)
-------------------------------------------------------------------------------------------------------------------
(Expressed in U.S. dollars)
Cumulative from
re-entering of
For the development
For the three month stage on
three month period ended 26 June 2010
period ended 28 28 February to 28 February
February 2014 2013 2014
Notes $ $ $
------------------------------------------------------- --------- ----------------- ---------------- -----------------
Expenses
Consulting 6, 8 - 75,000 552,975
Salaries and bonus 4, 6 157,940 159,000 1,228,024
General and administration 9 3,070 1,940 56,095
Professional fees 5,750 8,633 157,493
Supplies and materials 7,782 - 68,014
------------------------------------------------------- --------- ----------------- ---------------- -----------------
Net loss before other items (174,542) (244,573) (2,062,601)
------------------------------------------------------- --------- ----------------- ---------------- -----------------
Other items
Foreign exchange gain 3,711 1,136 5,825
Interest expense 5 (886) (927) (8,638)
------------------------------------------------------- --------- ----------------- ---------------- -----------------
Net loss for the period (171,717) (244,364) (2,065,414)
------------------------------------------------------- --------- ----------------- ---------------- -----------------
Other comprehensive loss
Foreign currency translation adjustment - - (333)
------------------------------------------------------- --------- ----------------- ---------------- -----------------
Total comprehensive loss for the period (171,717) (244,364) (2,065,747)
------------------------------------------------------- --------- ----------------- ---------------- -----------------
Basic and diluted comprehensive loss per common share (0.001) (0.002)
Weighted average number of shares outstanding 151,132,444 149,078,000
------------------------------------------------------- --------- ----------------- ---------------- -----------------
The accompanying notes are an integral part of these interim consolidated financial statements.
F-7
Peptide Technologies, Inc.
(A Development Stage Company)
Interim Consolidated Statements of Cash Flows
(Unaudited)
-------------------------------------------------------------------------------------------------------------------
(Expressed in U.S. dollars)
Cumulative from
For the For the re-entering of
three month three month development stage
period ended period ended on
28 February 28 February 26 June 2010
2014 2013 to 28 February 2014
Notes $ $ $
------------------------------------------------------------- -------- -------------- -------------- -----------------------
OPERATING ACTIVITIES
Net loss for the period (171,717) (244,364) (2,065,414)
Adjustments to reconcile net loss to cash used by operating
Accrued interest 5 886 927 8,638
Amortization 3 833 834 5,000
Foreign exchange gain (3,711) (1,136) (5,825)
Non-cash consulting expense 8 - - 2,000
Share-based payment - - 8,000
Changes in operating assets and liabilities
Decrease in prepaid expenses - 3,494 2,709
Increase in accounts payable and accrued liabilities 4, 6 164,420 237,245 1,825,943
------------------------------------------------------------- -------- -------------- -------------- -----------------------
Cash used in operating activities (9,289) (3,000) (218,949)
------------------------------------------------------------- -------- -------------- -------------- -----------------------
INVESTING ACTIVITIES
Purchase of website 3 - - (10,000)
------------------------------------------------------------- -------- -------------- -------------- -----------------------
Cash used in investing activities - - (10,000)
------------------------------------------------------------- -------- -------------- -------------- -----------------------
FINANCING ACTIVITIES
Proceeds from issuance of common shares, net of share
issuance costs 8 10,000 - 131,114
Increase (decrease) in notes payable 5 - - 67,212
Contribution by related party - - 27,288
------------------------------------------------------------- -------- -------------- -------------- -----------------------
Cash from (used in) financing activities 10,000 - 225,614
------------------------------------------------------------- -------- -------------- -------------- -----------------------
Effect of foreign exchange rate changes on cash - - (333)
------------------------------------------------------------- -------- -------------- -------------- -----------------------
Increase (decrease) in cash and cash equivalents 711 (3,000) (3,668)
Cash and cash equivalents, beginning of period 157 7,780 4,536
------------------------------------------------------------- -------- -------------- -------------- -----------------------
Cash and cash equivalents, end of period 868 4,780 868
------------------------------------------------------------- -------- -------------- -------------- -----------------------
Supplemental cash flow information (Note 12)
The accompanying notes are an integral part of these interim consolidated financial statements.
F-8
Peptide Technologies, Inc.
(A Development Stage Company)
Interim Consolidated Statements of Changes in Stockholders' Deficiency
(Unaudited)
-------------------------------------------------------------------------------------------------------------------
(Expressed in U.S. dollars)
Accumulated
Additional deficit during
paid-in Accumulated development
Number of Capital stock capital deficit stage Total
shares $ $ $ $ $
--------------------------------------- -------------- --------------- ------------- ------------- ----------------- ---------------
Balances, 30 November 2012 149,078,000 149,078 105,324 (105,837) (898,221) (749,656)
Shares issued for
Cash, net of share issuance costs 45,000 45 42,955 - - 43,000
Contractor services 2,000,000 2,000 - - - 2,000
Net loss for the year - - - - (995,476) (995,476)
--------------------------------------- -------------- --------------- ------------- ------------- ----------------- ---------------
Balances, 30 November 2013 151,123,000 151,123 148,279 (105,837) (1,893,697) (1,700,132)
--------------------------------------- -------------- --------------- ------------- ------------- ----------------- ---------------
Shares issued for cash 10,000 10 9,990 - - 10,000
Net loss for the period - - - - (171,717) (171,717)
--------------------------------------- -------------- --------------- ------------- ------------- ----------------- ---------------
Balances, 28 February 2014 151,133,000 151,133 158,269 (105,837) (2,065,414) (1,861,849)
--------------------------------------- -------------- --------------- ------------- ------------- ----------------- ---------------
The accompanying notes are an integral part of these interim consolidated financial statements.
F-9
Peptide Technologies, Inc.
(A Development Stage Company)
Notes to the Interim Consolidated Financial Statements
(Unaudited)
(Expressed in U.S. dollars)
--------------------------------------------------------------------------------
1. NATURE AND CONTINUENCE OF OPERATIONS
1.1 Organization
Peptide Technologies, Inc. (the "Company") was incorporated in the
State of Nevada, United States of America, on 18 November 2005. On 29
July 2010, the Company's name was changed from Online Originals, Inc.
to CREEnergy Corporation. Effective 12 October 2011, the Company's
name was changed from CREEnergy Corporation to Peptide Technologies,
Inc. The Company's year-end is 30 November. The Company is currently
a development stage Company.
On 5 August 2013, the Company incorporated Pept Peptide Technologies
Inc. ("Pept Peptide"), a wholly-owned subsidiary, under the laws of
British Columbia. Pept Peptide Technologies, Inc. currently does not
have any transactions from the date of incorporation on 5 August 2013
to 28 February 2014.
1.2 Nature of Operations and Change in Business
Upon inception on 18 November 2005, the Company's business plan was
to develop a membership-based website art gallery/auction house
specifically focused on displaying and selling original artwork. The
Company changed its status from a development stage company to an
operating company on 30 November 2009. Management realized that the
results of operations from the sale of artwork lacks luster and
decided to change the Company's business focus and plan for other
strategic opportunities. Effective 26 June 2010, the Company became a
development stage company focusing on a new business.
On 23 August 2011, the Company entered into an agreement (the "Asset
Purchase Agreement") in which the Company, in exchange for 75,000,000
shares of the Company's restricted common stock, received all rights
and title to proprietary technologies and formulas involving the
application of specialty Peptides. The Company has changed its
business focus to the manufacturing and distribution of natural
peptide solutions to combat the economic burden of bio-fouling. On 14
December 2011, the Company amended the Asset Purchase Agreement. As a
result of the amendment, the purchase price of the assets was reduced
from 75,000,000 shares to 45,000,000 shares, and 30,000,000 shares
were returned to treasury (Note 7).
The Company's business activities focus is on the development of
all-natural, sustainable solutions to the increasing problem of
bio-fouling and the development of safe "green" organic-based
fouling prevention products used to combat the rapidly growing
problems caused by the attachment of hard fouling agents in marine
and freshwater environments. This approach emphasizes minimizing the
attachment of hard fouling agents (mussels, barnacles, etc.) and
preventing the build-up of any bio-film layer as well.
F-10
Peptide Technologies, Inc.
(A Development Stage Company)
Notes to the Interim Consolidated Financial Statements
(Unaudited)
(Expressed in U.S. dollars)
--------------------------------------------------------------------------------
1.3 Basis of Going Concern
The accompanying interim consolidated financial statements as at 28
February 2014 and for the three month period then ended have been
prepared on a going concern basis, which contemplates the realization
of assets and settlement of liabilities and commitments in the normal
course of business. The Company has had a net loss of $171,717 for
the three month period ended 28 February 2014 (28 February 2013 -
$244,364; cumulative - $2,065,414 and has a working capital deficit
of $1,911,849 at 28 February 2014 (30 November 2013 - $1,750,965).
Management cannot provide assurance that the Company will ultimately
achieve profitable operations or become cash flow positive, or raise
additional debt and/or equity capital. Management believes that the
Company's capital resources should be adequate to continue operating
and maintaining its business strategy during the fiscal year ended 30
November 2014. However, if the Company is unable to raise additional
capital in the near future or met financing requirements, due to the
Company's liquidity problems, management expects that the Company
will need to curtail operations, liquidate assets, seek additional
capital on less favorable terms and/or pursue other remedial
measures. Management is aware, in making its assessment, of material
uncertainties related to events or conditions that may cast
significant doubt upon the Company's ability to continue as a going
concern. These interim consolidated financial statements do not
include any adjustments related to the recoverability and
classification of assets or the amounts and classification of
liabilities that might be necessary should the Company be unable to
continue as a going concern.
Although management is actively seeking to add new products and/or
services in order to show profitability, and is seeking additional
sources of equity or debt financing, there is no assurance that these
activities will be successful. The Company has not yet been able to
find products and services that would contribute to their business
due to the continued economic condition. These factors raise
substantial doubt about the ability of the Company to continue as a
going concern. The interim consolidated financial statements do not
include any adjustments that might result from the outcome of this
uncertainty.
1.4 Unaudited Statements
While the information presented in the accompanying interim
consolidated financial statements is unaudited, it includes all
adjustments which are, in the opinion of management, necessary to
present fairly the financial position, results of operations and cash
flows for the interim periods presented. Except as disclosed below,
these interim consolidated financial statements follow the same
accounting policies and methods of their application as the Company's
audited 30 November 2013 annual consolidated financial statements. It
is suggested that these interim consolidated financial statements be
read in conjunction with the Company's audited consolidated financial
statements for the year ended 30 November 2013, included in the
annual report previously filed with the Securities and Exchange
Commission on Form 10-K. The results of operations for the interim
periods presented are not necessarily indicative of the results to be
expected for the full year.
The information as of 30 November 2013, is taken from the audited
consolidated financial statements as of that date.
F-11
Peptide Technologies, Inc.
(A Development Stage Company)
Notes to the Interim Consolidated Financial Statements
(Unaudited)
(Expressed in U.S. dollars)
--------------------------------------------------------------------------------
2. SIGNIFICANT ACCOUNTING POLICIES
This summary of significant accounting policies is presented to assist in
understanding the Company's interim consolidated financial statements. The
interim consolidated financial statements and notes are representations of
management who is responsible for their integrity and objectivity. These
accounting policies have been consistently applied in the preparation of
the interim consolidated financial statements.
2.1 Basis of Presentation
These interim consolidated financial statements have been prepared in
accordance with accounting principles generally accepted in the
United States of America ("U.S. GAAP") applicable for a development
stage company for financial information and are expressed in U.S.
dollars.
2.2 Principles of Consolidation
These interim consolidated financial statements include the accounts
of the Company and its wholly-owned subsidiary Pept Peptide
Technologies, Inc., a company incorporated in the province of British
Columbia on 5 August 2013. All significant inter-company balances
and transactions have been eliminated upon consolidation.
2.3 Organizational and Start-up Costs
Costs of start-up activities, including organizational costs, are
expensed as incurred in accordance with Accounting Standards
Codification ("ASC") 720-15, "Start-Up Costs".
2.4 Development-Stage Company
During the year ended 30 November 2010, the Company abandoned its
previous business of sale of original artwork and re-entered the
development stage with its intended new business, which currently has
no revenues. Management expects to sustain losses from operations
until such time it can generate sufficient revenues to meet its
anticipated cost structure. The Company is considered a
development-stage company in accordance with the ASC 915, "Accounting
and Reporting by Development-Stage Enterprises". A development-stage
enterprise is one in which planned principal operations have not
commenced or if its operations have commenced, there has been no
significant revenues there from.
2.5 Cash and Cash Equivalents
Cash and cash equivalents include highly liquid investments with
original maturities of three months or less.
F-12
Peptide Technologies, Inc.
(A Development Stage Company)
Notes to the Interim Consolidated Financial Statements
(Unaudited)
(Expressed in U.S. dollars)
--------------------------------------------------------------------------------
2.6 Website
In accordance with ASC 350-50, "Website Development Costs",
expenditures during the planning and operating stages of the
Company's website are expensed as incurred. Expenditures incurred
during the website application and infrastructure development stage
are capitalized and amortized to expense over the website's estimated
useful life of 3 years.
2.7 Intangible Assets
Intangible assets include the cost of acquiring the intellectual
property. In accordance with ASC 350-30 "General Intangibles Other
Than Goodwill", an intangible asset that is acquired either
individually or with a group of other assets shall be recognized.
Costs of internally developing, maintaining, or restoring intangible
assets that are not specifically identifiable, that have
indeterminate lives, or that are inherent in a continuing business
and related to an entity as whole, shall be recognized as an expense
when incurred. The intellectual property is determined to have an
indefinite useful life and is not subject to amortization. The useful
life of the intangible asset is reassessed at each reporting period.
2.8 Impairment of Long-Lived Assets
Long-lived assets include the website and intangible assets and
intellectual property. Long-lived assets subject to amortization are
reviewed for impairment whenever events or changes in circumstances
indicate that the carrying amount of an asset may not be recoverable.
Long-lived assets not subject to amortization are tested for
impairment annually or more frequently if events or changes in
circumstances indicate that the asset might be impaired.
Recoverability of assets to be held and used is measured by a
comparison of the carrying amount of an asset to the estimated
undiscounted future cash flows expected to be generated by the asset.
If the carrying amount of an asset exceeds its estimated future cash
flows, an impairment charge is recognized as the amount by which the
carrying amount of the asset exceeds the fair value of the asset.
There has been no impairment as of 28 February 2014.
2.9 Research and Development
Research and development expenses are charged to operations as
incurred.
2.10 Income Taxes
The Company adopted the ASC 740, "Accounting for Income Taxes". ASC
740 requires the use of the asset and liability method of accounting
of income taxes. Under the asset and liability method of ASC 740,
deferred tax assets and liabilities are recognized for the future tax
consequences attributable to temporary differences between the
interim consolidated financial statements carrying amounts of
existing assets and liabilities and their respective tax bases.
Deferred tax assets and liabilities are measured using enacted tax
rates expected to apply to taxable income in the years in which those
temporary differences are expected to be recovered or settled. A
valuation allowance is established when necessary to reduce deferred
tax assets to the amount expected to be realized.
F-13
Peptide Technologies, Inc.
(A Development Stage Company)
Notes to the Interim Consolidated Financial Statements
(Unaudited)
(Expressed in U.S. dollars)
--------------------------------------------------------------------------------
2.11 Basic and Diluted Income (Loss) per Share
In accordance with ASC 260, "Earnings per Share", the basic loss per
common share is computed by dividing net loss available to common
stockholders by the weighted average number of common shares
outstanding. Diluted loss per common share is computed similar to
basic loss per common share except that the denominator is increased
to include the number of additional common shares that would have
been outstanding if the potential common shares had been issued and
if the additional common shares were dilutive. Diluted earnings per
share are not shown for periods in which the Company incurs a loss
because it would be anti-dilutive. At 28 February 2014, the Company
had no stock equivalents that were anti-dilutive and excluded in the
earnings per share computation.
2.12 Estimated fair value of financial instruments
The carrying value of the Company's interim consolidated financial
instruments, consisting of cash, accounts payable and notes payable
approximate their fair value due to the short-term maturity of these
instruments. Unless otherwise noted, it is management's opinion that
the Company is not exposed to significant interest or currency risks
arising from these financial statements.
Financial instruments that potentially subject the Company to
concentrations of credit risk consist principally of cash and cash
equivalents. At 28 February 2014, all cash and cash equivalents were
insured by agencies of the U.S. Government.
2.13 Foreign Currency Translation
The interim consolidated financial statements are presented in U.S.
dollars. In accordance with ASC 830 "Foreign Currency Matters",
foreign denominated monetary assets and liabilities are translated to
their U.S. dollar equivalents using foreign exchange rates which
prevailed at the balance sheet date. Revenue and expenses are
translated at average rates of exchange during the period. Related
translation adjustments are reported as a separate component of
stockholders' equity, whereas gains or losses resulting from foreign
currency transactions are included in results of operations.
2.14 Comprehensive Income (Loss)
The Company adopted ASC 220, "Reporting Comprehensive Income". ASC
220 requires that the components and total amounts of comprehensive
income be displayed in the interim consolidated financial statements
beginning in 1998. Comprehensive income includes net income and all
changes in equity during a period that arises from non-owner sources,
such as foreign currency items and unrealized gains and losses on
certain investments in equity securities.
F-14
Peptide Technologies, Inc.
(A Development Stage Company)
Notes to the Interim Consolidated Financial Statements
(Unaudited)
(Expressed in U.S. dollars)
--------------------------------------------------------------------------------
2.15 Use of Estimates
The preparation of the Company's interim consolidated financial
statements are in conformity with U.S. GAAP which requires management
to make estimates and assumptions that affect the amounts reported in
these consolidated financial statements and accompanying notes.
Actual results could differ from those estimates.
2.16 Changes in Accounting Policy
Effective 1 December 2013, the Company adopted Financial Accounting
Standards Board ("FASB") Accounting Standards Update ("ASU") No.
2013-02, "Comprehensive Income". This update requires an entity to
present information about amounts reclassified out of accumulated
other comprehensive income and their corresponding effect on the
respective line items in net income in one place, and in some cases,
cross-references to related footnote disclosures. The update applies
to public companies for all reporting periods presented, including
interim periods, and to nonpublic entities for annual reporting
periods. ASU No. 2013-02 will be effective for fiscal years, and
interim periods within those years, beginning after 15 December 2012
for public companies, with early adoption permitted. The adoption of
this update did not have a material effect on the Company's interim
consolidated financial statements
2.17 Recent Accounting Pronouncements
In July 2013, the FASB issued ASU No. 2013-11, "Presentation of an
Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a
Similar Tax Loss, or a Tax Credit Carryforward Exists", which is
intended to eliminate the diversity that is in practice with regard
to the financial statement presentation of unrecognized tax benefits
when a net operating loss carryforward, a similar tax loss, or a tax
credit carryforward exists. ASU No. 2013-11 is effective for fiscal
years and interim periods within those years, beginning after 15
December 2014, with early adoption permissible. The adoption of this
update is not expected to have a material impact on the Company's
interim consolidated financial statements.
2.18 Reclassifications
Certain amounts reported in previous periods have been reclassified
to conform to the current presentation.
2.19 Other
The Company consists of one reportable business segment.
The Company paid no dividends during the periods presented.
F-15
Peptide Technologies, Inc.
(A Development Stage Company)
Notes to the Interim Consolidated Financial Statements
(Unaudited)
(Expressed in U.S. dollars)
--------------------------------------------------------------------------------
3. WEBSITE
-------------------------------------------- --------------------------------------------
As at: 30 November 2013
28 February 2014 (Audited)
----------- ----------------- -------------- ----------- ----------------- --------------
Accumulated Net book Accumulated Net book
Cost amortization value Cost amortization value
$ $ $ $ $ $
----------- ----------------- -------------- ----------- ----------------- --------------
Website 10,000 5,000 5,000 10,000 4,167 5,833
-------------------------- ----------- ----------------- -------------- ----------- ----------------- --------------
Total 10,000 5,000 5,000 10,000 4,167 5,833
-------------------------- ----------- ----------------- -------------- ----------- ----------------- --------------
The Company purchased a website during October 2012 for $10,000. This
website has a useful life of three 3 years, and the cost is being amortized
over the life of the asset. During the three month period ended 28 February
2014, the Company recognized amortization expense of $833 (28 February 2013
- $834; cumulative - $5,000) (Note 9).
4. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
As at: 28 February 30 November 2013
2014 (Audited)
$ $
-------------------------------------------------- ---------------------- ---------------------
Accounts payable 590,668 574,188
Accrued liabilities 17,000 27,000
Payroll taxes payable 22,024 17,084
Salaries and benefits payable (Notes 6 and 11) 1,197,000 1,044,000
-------------------------------------------------- ---------------------- ---------------------
Total accounts payable and accrued liabilities 1,826,692 1,662,272
-------------------------------------------------- ---------------------- ---------------------
Trades payable and accrued liabilities are non-interest bearing, unsecured
and have settlement dates within one year.
Included in salaries and benefits payable, are $300,000 (30 November 2013 -
$300,000) of bonuses payable to the Chief Executive Officer ("CEO") of the
Company as at 28 February 2014 (Note 6).
Included in accounts payable and accrued liabilities is $545,000 (30
November 2013 - $545,000) payable to a related party of the Company as at
28 February 2014 (Notes 6 and 11).
The Company is in the process of completing and resolving issues related to
its income tax filings and has accrued $10,000 during the year ended 30
November 2013 related to potential penalties associated with these filings.
However, there is no assurance that additional interest and penalties will
not be assessed (Notes 9, 10 and 11).
F-16
Peptide Technologies, Inc.
(A Development Stage Company)
Notes to the Interim Consolidated Financial Statements
(Unaudited)
(Expressed in U.S. dollars)
--------------------------------------------------------------------------------
5. NOTES PAYABLE AND ACCRUED INTEREST
As at: 30 November 2013
28 February 2014 (Audited)
$ $
-------------------------------------------------------------------- ----------------- ------------------
During the year ended 30 November 2010, Fotoview Inc. ("Fotoview") issued a
loan of $16,000 to a former director of the Company to purchase 4,000,000
restricted common shares of the Company. Upon the director's resignation,
the 4,000,000 common shares were cancelled and the Company assumed the loan
payable to Fotoview. The loan is unsecured, bears no interest, and has no
fixed terms of repayment. 16,000 16,000
On 21 September 2011, PSI Services ("PSI") issued a loan of $500 to the
Company. The loan is unsecured, bears no interest and has
no fixed terms of repayment. 500 500
On 13 November 2011, PSI issued a loan of CAD$45,000 to the Company. 45,982 47,961
The loan is unsecured and bears no interest at a rate of 6% per annum.
Principal and accrued interest is due on 30 November 2014. During the three
month period ended 28 February 2014, the Company accrued interest expense
of $613 (28 February 2013 - $642) (Note 12). The loan payable to PSI as at
28 February 2014 consists of principal and accrued interest of $40,415
(30 November 2013 - $42,710) and $5,567 (30 November 2013 - $5,251),
respectfully.
On 1 June 2012, PSI issued a loan of CAD$20,000 to the Company. The loan is
unsecured and bears interest at a rate of 6% per annum. Principal and
accrued interest is due on 30 November 2014. During the three months ended
28 February 2014, the Company accrued interest expense of $273 (28 February
2013 - $285) (Note 12). The loan payable to PSI as at 28 February 2014
consists of principal and accrued interest of $17,962 (30 November 2013
-$18,982) and $1,881 (30 November 2013 - $1,707), respectively. 19,843 20,689
On 22 October 2013, PSI issued a loan of USD$3,700 to the Company. The loan
is unsecured, bears no interest, and has no fixed terms of repayment. 3,700 3,700
-------------------------------------------------------------------- ----------------- ------------------
Total notes payable and accrued interest 86,025 88,850
-------------------------------------------------------------------- ----------------- ------------------
F-17
Peptide Technologies, Inc.
(A Development Stage Company)
Notes to the Interim Consolidated Financial Statements
(Unaudited)
(Expressed in U.S. dollars)
--------------------------------------------------------------------------------
6. RELATED PARTY TRANSACTIONS
As at 28 February 2014, the amount due to related parties includes
$1,197,000 payable to directors and employees of the Company in relation to
salaries and benefits earned (30 November 2013 - $1,044,000). Of the amount
due to related parties, $300,000 relates to bonuses payable to the CEO of
the Company (30 November 2013 - $300,000) (Note 4).
During the three month period ended 28 February 2014, the Company accrued
salaries and benefits of $153,000 to officers and employees of the Company
(28 February 2013 - $153,000; cumulative - $1,206,000) (Note 11). Included
in salaries and benefits, are bonuses of $Nil accrued to the CEO of the
Company during the three month period ended 28 February 2014 (28 February
2013 - $Nil; cumulative - $300,000).
Effective 1 December 2013, the Company and a former related party
consultant mutually terminated an Advisory Agreement entered into on 1
November 2012. The Company accrued $Nil of consulting fees to the
consultant (28 February 2013 - $75,000; cumulative - $545,000) during the
three month period ended 28 February 2014. As at 28 February 2014 there is
$545,000 (30 November 2013 - $545,000) outstanding and payable to the
consultant for consulting services received (Notes 4 and 11).
During the year ended 30 November 2013, the Board approved a commission
payment program (the "Program") equal to 30% of gross sales of fouling
prevention coatings. Under this program, the CEO will receive compensation
equal to 20% of gross sales of anti-fouling paint, as recognition of his
work in developing the formulas; and an external consultant will receive
10% of gross sales of anti-fouling paint as compensation for sales
development. On 28 February 2014, the Board amended the Program to reduce
the CEO's compensation from 20% to 10% of gross sales of anti-fouling paint
(Notes 7 and 11).
During the three month period ended 28 February 2014, directors and
shareholders of the Company made cash contributions in the amount of $Nil
(28 February 2013 - $Nil, cumulative - $27,288).
7. INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY
On 23 August 2011, the Company entered into an Asset Purchase Agreement to
acquire intangible assets and intellectual property known as the Platforms
in exchange for 75,000,000 restricted common shares of the Company (issued
on 23 August 2011) (Note 1).
On 14 December 2011, the Company entered into an Amended Asset Purchase
Agreement and, as a result, a total of 30,000,000 restricted common shares
of the Company were returned to treasury and cancelled in exchange for
payment of half of one percent of all gross monies received by the Company
in relation to revenue earned from products derived from the use of all the
formulae listed in the Assets Purchase Agreement. In addition, a monthly
stipend of CAD $15,000 per month is to be paid commencing on the receipt of
monies from the first contract signed to purchase products derived from the
use of the formulae for a period of five years from the date of the Amended
Asset Purchase Agreement. The cancellation of 30,000,000 common shares has
been recorded as a recovery of intangible assets and intellectual property
(Notes 1 and 11).
F-18
Peptide Technologies, Inc.
(A Development Stage Company)
Notes to the Interim Consolidated Financial Statements
(Unaudited)
(Expressed in U.S. dollars)
--------------------------------------------------------------------------------
On 20 January 2013, the Board approved a commission payment program equal
to 30% of gross sales of fouling prevention coatings. Under this program,
the CEO will receive compensation equal to 20% of gross sales of
anti-fouling paint, as recognition of his work in developing the formulas;
and an external consultant will receive 10% of gross sales of anti-fouling
paint as compensation for sales development. On 28 February 2014, the Board
amended the Program to reduce the CEO's compensation from 20% to 10% of
gross sales of anti-fouling paint (Notes 6 and 11).
8. CAPITAL STOCK
8.1 Authorized common stock
The Company's authorized common stock consists of 675,000,000 shares
of common stock with a par value of $0.001 per share. On 10 August
2010, the Company increased the number of authorized share capital
from 75,000,000 shares of common stock to 675,000,000 shares of
common stock with the same par value of $0.001 per share.
8.2 Issued and outstanding
On 2 June 2010, and effective 10 August 2010, the directors of the
Company approved a forward split of the common stock of the Company
on a basis of 30 new common shares for 1 old common share. As a
result of the forward stock split, 208,800,000 additional shares were
issued. Capital and additional paid-in capital have been adjusted
accordingly. When adjusted retroactively, there was a $119,501
shortage of additional paid-in capital; thus an adjustment to
accumulated deficit of $104,000 was recorded on 20 May 2010 (the date
of issuance of 120,000,000 shares) and $15,501 to the beginning
balance. The interim consolidated financial statements contained
herein reflect the appropriate values for capital stock and
accumulated deficit. Unless otherwise noted, all references in the
accompanying interim consolidated financial statements to the number
of common shares and per share amounts have been retroactively
restated to reflect the forward stock split.
The total issued and outstanding capital stock is 151,133,000 common
shares with a par value of $0.001 per common share. The Company's
common stock issuances to date are as follows:
a) On 10 April 2013, the Company issued 20,000 shares of the
Company's restricted common stock for cash proceeds of $20,000.
The Company paid $2,000 in share issuance costs.
b) On 26 April 2013, the Company issued 2,000,000 shares of the
Company's restricted common stock at a par value of $0.001 per
share to a third party for marketing assistance with the
development of the international markets in the South Pacific
quadrant for the Company. As a result, the Company recorded
consulting expense of $2,000 when the stock was issued (Note 12).
c) On 18 July 2013, the Company issued 25,000 shares of the
Company's restricted common stock for cash proceeds of $25,000.
d) On 3 December 2013, the Company issued 10,000 shares of the
Company's restricted common for cash proceeds of $10,000.
F-19
Peptide Technologies, Inc.
(A Development Stage Company)
Notes to the Interim Consolidated Financial Statements
(Unaudited)
(Expressed in U.S. dollars)
--------------------------------------------------------------------------------
9. GENERAL AND ADMINISTRATION EXPENSES
Cumulative from
re-entering of
development
stage on
Three month Three month 26 June 2010
period ended 28 period ended 28 to 28 February
February 2014 February 2013 2014
$ $ $
---------------------------------------------------- ------------------- ------------------ ------------------
Administration - - 20
Amortization (Note 3) 833 834 5,000
Bank charges 83 72 1,367
Dues and subscription - - 575
Filing fees 721 25 12,191
Meals and entertainment - - 254
Office 69 197 6,792
Penalties - - 10,000
Transfer agent 295 150 3,796
Rent 269 193 1,502
Share-based payment - - 8,000
Telecommunication 800 61 3,793
Travel - 408 2,656
Website - - 149
---------------------------------------------------- ------------------- ------------------ ------------------
Total general and administration expenses 3,070 1,940 56,095
---------------------------------------------------- ------------------- ------------------ ------------------
F-20
Peptide Technologies, Inc.
(A Development Stage Company)
Notes to the Interim Consolidated Financial Statements
(Unaudited)
(Expressed in U.S. dollars)
--------------------------------------------------------------------------------
10. INCOME TAXES
10.1 Provision for income taxes
Income tax expense differs from the amount that would result from
applying the federal income tax rate to earnings before income taxes.
During the three month periods ended 28 February 2014 and 2013, these
differences result from the following items:
For the Three For the Three
Month Period Month Period
Ended 28 Ended 28
February 2014 February 2013
$ $
-------------------------------------------------------- ----------------- -----------------
Loss before income taxes 171,171 244,364
Federal income tax rates 35.00% 35.00%
-------------------------------------------------------- ----------------- -----------------
Income tax recovery based on the above rates (60,101) (85,527)
Non-deductible items - -
Change in valuation allowance 60,101 85,527
-------------------------------------------------------- ----------------- -----------------
Income tax expense - -
-------------------------------------------------------- ----------------- -----------------
10.2 Deferred tax balances
The composition of the Company's deferred tax assets as at 28
February 2014 and 30 November 2013 are as follows:
As at: 28 February 30 November 2013
2014 (Audited)
$ $
------------------------------------------------------------------- ---------------- --------------------
Net income tax operating loss carry-forward 2,147,624 1,975,908
------------------------------------------------------------------- ---------------- --------------------
Deferred tax assets 751,669 691,568
Valuation allowance (751,669) (691,568)
------------------------------------------------------------------- ---------------- --------------------
Deferred tax assets (liabilities) - -
------------------------------------------------------------------- ---------------- --------------------
F-21
Peptide Technologies, Inc.
(A Development Stage Company)
Notes to the Interim Consolidated Financial Statements
(Unaudited)
(Expressed in U.S. dollars)
--------------------------------------------------------------------------------
As at 28 February 2014, the Company has a total non-capital loss
carryforward balance of $2,147,624 (30 November 2013 - 1,975,908),
which has expiry dates between the years of 2025 to 2034.
The Company's recognized and unrecognized deferred tax assets related
to the unused tax losses. A full valuation allowance has been
recorded against the potential deferred tax assets associated with
all the loss carry-forwards as their utilization is not considered
more likely than not at this time.
The Company is in the process of completing and resolving issues
related to its income tax filings and has accrued $10,000 during the
year ended 30 November 2013 related to potential penalties associated
with these filings. However, there is no assurance that additional
interest and penalties will not be assessed (Notes 4, 9 and 11).
11. COMMITMENTS AND CONTINGENCY
a) The Company is committed to paying one-half of one percent of all gross
monies received by the Company from revenue produced from products
derived from the use of all the formula listed in the Assets Purchase
Agreement. In addition, a monthly stipend of CAD $15,000 per month is
to be paid commencing from receipt of monies from the first contract
signed to purchase products derived from the use of the formula for a
period of five years from the date of the Amended Asset Purchase
Agreement (Note 7).
b) On 20 January 2013, the Board approved a commission payment program
equal to 30% of gross sales of fouling prevention coatings. Under this
program, the CEO will receive compensation equal to 20% of gross sales
of anti-fouling paint, as recognition of his work in developing the
formulas; and an external consultant will receive 10% of gross sales of
anti-fouling paint as compensation for sales development. On 28
February 2014, the Board amended the Program to reduce the CEO's
compensation from 20% to 10% of gross sales of anti-fouling paint
(Notes 6 and 7).
c) On 1 November 2012, the Company entered into an advisory agreement with
a consultant. The commitment is for a term of five years, with the
Company being able to terminate the agreement with 30 days written
notice. Effective 1 December 2013, the Company and the consultant
mutually terminated and Advisory Agreement. As at 28 February 2014
there is $545,000 (30 November 2013 - $545,000) outstanding and payable
to the consultant in relation to consulting services received (Notes 4
and 6).
d) Effective 1 September 2012, the Company is committed to paying monthly
salaries of $25,000 to the CEO, $20,000 to the Chief Financial Officer
("CFO"), and $6,000 to the Vice President of Operations & Communication
("VP of Operations & Communications") (Notes 4 and 6).
e) On 11 December 2012, the Company formerly engaged BB&T Capital Markets
("BB&TCM") to act as the Company's exclusive financial advisor and
agent in connection with developing strategic alternatives for the
Company regarding debt financings, licensing of intellectual properties
developed by the Company, equity raises, sale of intellectual
properties, or other capital markets transactions that may develop over
the course of a 24 month agreement.
The Company is to pay BB&TCM an advisory fee of three percent of the
face amount of the financial transactions advised upon during the
course of the engagement, due and payable at closing of any
contemplated transactions under the engagement.
F-22
Peptide Technologies, Inc.
(A Development Stage Company)
Notes to the Interim Consolidated Financial Statements
(Unaudited)
(Expressed in U.S. dollars)
--------------------------------------------------------------------------------
Additionally, the Company is to defend, indemnify and hold BB&TCM, its
parent company, subsidiaries and affiliates and its and their
directors, officers, employees, agents and successors and assigns
harmless from and against any losses, suits, actions, claims, damages,
costs and or other liabilities which any indemnified person may incur
as a result of acting on behalf of the Company in connection with this
engagement.
f) The Company is in the process of completing certain of its income tax
filings and has accrued $10,000 during the year ended 30 November 2013
related to potential penalties associated with these filings. However,
there is no assurance that additional interest and penalties will be
assessed (Notes 4, 9 and 10).
12. SUPPLEMENTAL CASH FLOW INFORMATION
The Company made the following cash payments for interest and income taxes:
Three month
Three month period ended
period ended 28 28 February
February 2014 2013
$ $
--------------------------------------- ------------------ ----------------
Interest paid - -
Taxes paid - -
--------------------------------------- ------------------ ----------------
Total cash payments - -
--------------------------------------- ------------------ ----------------
On 26 April 2013, the Company issued 2,000,000 fully vested shares of the
Company's restricted common stock at a par value of $0.001 per share to a
third party for marketing assistance with the development of the
international markets in the South Pacific quadrant for the Company. As a
result, the Company recorded consulting expense of $2,000 when the stock
was issued (Note 8).
During the three month period ended 28 February 2014, the Company accrued
interest expense of $613 (28 February 2013 - $642) in relation to a loan of
CAD$45,000 issued by PSI on 13 November 2011. The loan is unsecured and
bears interest at a rate of 6% per annum (Note 5).
During the three month period ended 28 February 2014, the Company accrued
interest expense of $273 in relation to a loan of CAD$20,000 issued by PSI
on 1 June 2012. The loan is unsecured and bears interest at a rate of 6%
per annum (Note 5).
F-23
Peptide Technologies, Inc.
(A Development Stage Company)
Notes to the Interim Consolidated Financial Statements
(Unaudited)
(Expressed in U.S. dollars)
--------------------------------------------------------------------------------
13. SUBSEQUENT EVENTS
The following reportable events occurred during the period from the three
month period ended 28 February 2014 to the date the interim consolidated
financial statements were available to be issued on 8 April 2014.
a) On 3 March 2014, the Company issued 10,000 shares of the Company's
restricted common shares for cash proceeds of $10,000.
b) On 11 March 2014, the Company issued 5,000 shares of the Company's
restricted common shares for cash proceeds of $5,000.
F-24
Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATIONS
The following discussion should be read in conjunction with our unaudited
financial statements and notes thereto included herein. In connection with, and
because we desire to take advantage of, the "safe harbor" provisions of the
Private Securities Litigation Reform Act of 1995, we caution readers regarding
certain forward looking statements in the following discussion and elsewhere in
this report and in any other statement made by, or on our behalf, whether or not
in future filings with the Securities and Exchange Commission. Forward-looking
statements are statements not based on historical information and which relate
to future operations, strategies, financial results, or other developments.
Forward-looking statements are necessarily based upon estimates and assumptions
that are inherently subject to significant business, economic, and competitive,
uncertainties and contingencies, many of which are beyond our control and many
of which, with respect to future business decisions, are subject to change.
These uncertainties and contingencies can affect actual results and could cause
actual results to differ materially from those expressed in any forward-looking
statements made by or on our behalf. We disclaim any obligation to update
forward-looking statements.
The following discussion of the plan of operation, financial condition, results
of operations, cash flows and changes in financial position of our Company
should be read in conjunction with our most recent financial statements and
notes appearing elsewhere in this Quarterly Report on Form 10-Q, and our Annual
Report on Form 10-K filed on February 28, 2014.
The independent registered public accounting firms' reports on the Company's
financial statements as of November 30, 2013, and for the year then ended,
include a "going concern" explanatory paragraph that describes substantial doubt
about the Company's ability to continue as a going concern. Management's plans
in regard to the factors prompting the explanatory paragraph are discussed below
and also in Note 1 to the unaudited quarterly financial statements.
Discontinued Operations and New Developments
Since inception, the Company's business plan was to develop a membership based
website art gallery/auction house specifically focused on displaying and selling
original artwork. The Company changed its status from a development stage
company to an operating company on November 30, 2009. Management realized that
the results of operations from the sale of artwork was lack-luster, and it was
decided to change the Company's business focus and plan for other strategic
opportunities and discontinued the sale of artwork to be effective June 25,
2010. Effective June 26, 2010, the Company started to focus on a new business
development. On July 29, 2010, the Company's name changed from Online Originals,
Inc. to Creenergy Corporation. The name change was intended to convey a sense of
the Company's new business focus as it looked to pursue other opportunities.
Specifically, the Company intended to obtain leases for the exploration and
production of oil and gas in northern Canada and the United States. These
objectives have not been realized and the Company has abandoned its efforts in
this area.
On August 23, 2011, the Company entered into an agreement (the "Asset Purchase
Agreement") in which the Company issued a total of 75,000,000 shares of its
restricted common stock in exchange for intangible assets and intellectual
property referred to as the Peptide Technology Platforms. 60,000,000 of these
restricted shares were issued equally; 30,000,000 shares to William Campbell and
30,000,000 shares to Scott McKinley. The balance of 15,000,000 restricted shares
was issued equally; 7,500,000 shares to Deborah Fortescue-Merrin and 7,500,000
shares to Richard Fortescue. Upon their resignations, Deborah Fortescue-Merrin
and Richard Fortescue each relinquished 6,500,000 shares of common stock to
Scott McKinley upon his acceptance of Chief Executive Officer for the Company.
The assets that were purchased were set aside and new formulations were
developed by the company.
On December 14, 2011, the Peptide Technologies, Inc. agreed to amend the Asset
Purchase Agreement dated August 23, 11. As a result of the amendment,
30,000,000 restricted common shares of the Company issued to William Campbell
were returned to the treasury in exchange for payment of half of the one percent
of all gross monies received by the company from revenue produced from products
derived from the use of all the formulae listed in the Asset Purchase Agreement.
In addition a monthly stipend of CDN $15,000 per month is to be paid commencing
from receipt of monies from the first contract signed to purchase products
derived from the use of the formulae for a period of five years from the date of
the amended agreement.
25
Business of Issuer
Peptide Technologies, Inc. has developed the first all-natural sustainable
solution for the economic and environmental burden of bio-fouling to prevent the
attachment of organic matter on ship hulls and marine assets to improve vessel
fuel efficiency, decrease maintenance costs, reduce emissions and prevent toxic
materials in our oceans, lakes and valuable water sources.
Our product line offers safe organic-based fouling prevention coatings used to
combat the rapidly growing problems caused by the attachment of hard fouling
agents in the marine and freshwater environments. Peptide Technologies' patent
protected approach not only significantly minimizes the attachment of hard
fouling agents such as mussels, barnacles, etc. but is also highly effective in
preventing the build-up of any bio-film layer as well. Our products offer an
industry first "30 MINUTE" curing phase to significantly lower maintenance dry
dock downtime.
Our organic-based solutions are highly effective in both marine and freshwaters
and are the first non-dangerous, non-hazardous and therefore environmentally
friendly products available to the aquatic and industrial market. Our fouling
prevention coatings adhere to both stationary and flexible substrates (i.e.
netting) and are available in a variety of colors. There are many benefits to
applying our fouling prevention coatings in enclosed systems as well as open
surfaces such as ship hulls, fish nets, intake screens, canal gates where the
application of paint containing biocides, bio-pesticides or copper products
and/or chemical based is not appropriate.
Targeted applications for our products are:
o Hydro-electric facilities and dams (i.e., water in-take pipes,
valves);
o Ship hulls (i.e., barnacle covered hulls can increase fuel usage by
more than 40%);
o Commercial fish nets;
o Pearling and Aquaculture industry;
o Drinking water treatment facilities;
o Farm irrigation water;
o Navigation locks;
o Oil rigs (FPSO);
o Other cement and/or steel substrates; and
o Concrete residential and commercial buildings
Unlike any other anti-fouling paint in the world, Peptide Technologies' fouling
prevention coatings are the only ones in the world to receive a non-hazardous
and non-dangerous rating by Risk Management Technology firm ChemAlert of
Australia with a documented Government sanctioned certification. More
information can be found here:
http://peptidetechnologiesinc.com/about-us/certifications/
----------------------------------------------------------
OUR PRODUCT LINE
----------------
Peptide Technologies is pleased to introduce four products designed to prevent
the attachment of fouling organisms to a variety of substrates:
>> AquaNatural Industrial Coating- customized formulation to provide
effective protection from fouling organisms onto fixed assets for 10
years.
>> AquaCrete Natural Coating- customized solution to provide effective
protection to concrete surfaces from fouling organisms for 10 years.
26
>> AquaCulture Natural Coating- designed for flexible substrates such as
netting to allow for expansion and contraction without compromising
integrity of the coating for 2 years.
>> AquaNatural Marine Coating- customizable friction reduction formula
for assets while stationary or mobile for 5 years resulting in a
potential 5-6% fuel cost savings.
Together, these coatings will prevent attachment of fouling organisms to bare
wood, carbon steel, galvanized steel, stainless steel, concrete, gel coats,
underwater cable coverings and polypropylene netting. Coatings are non-hazardous
and do not kill fouling agents. Coatings are designed to simply prevent
organisms such as algae and other hard organisms (i.e. barnacles, mussels) from
attaching to the substrate. In addition, coatings can be formulated to provide
protection from fouling organisms onto fixed assets for 10 years (AquaNatural
Industrial and AquaCrete Natural Coatings).
Furthermore, the incorporation of silicone into our coatings has been carefully
tuned to not interfere with the slow release of the active ingredients. Indeed,
the silicone provides a hydrophobic environment at the coated substrate/water
interface. Empirical data obtained from a laboratory designed flume suggests a
reduction in drag of >5%. As a result, our coating will contribute to an overall
savings in fuel costs for mobile assets for a period of 5 years (AquaNatural
Marine Coating).
AquaCulture Natural Coating has been designed to expand and contract without
compromising the integrity of the coating. Open net-pens, anchor ropes and other
substrates influenced by the action of water currents can be coated and
protected from fouling by the flexible nature of this coating. The coating is
designed to provide effective substrate coating protection for 2 years.
OUR PROVEN RESULTS
------------------
Peptide Technologies products are the world's first coating to be classified as
a non-hazardous and non-dangerous good (Chem Alert - Australia) of all of the
registered fouling prevention paints for both fresh and marine environments. The
effectiveness of the coating at preventing the attachment of fouling organisms
has been examined and independently monitored at locations around the globe
including: Darwin, Australia, Niagara Falls, Canada, Colorado River, USA,
Trondheim, Norway and Vancouver, Canada. Results from all these locations showed
the coatings significantly prevented fouling attachment for periods up to 8
months.
Our coatings contain no biocides, are non-dangerous, non-hazardous and free of
any regulated active ingredients (DSL and TSCA). The absence of copper from any
of our coatings allows for application of our products to include spraying
without contamination to neighboring waters.
http://www.environment.nsw.gov.au/resources/sustainbus/2007108_mbs_sheet4.pdf.
Our products can be produced in multiple colors including clear and white.
Furthermore the 30 minute quick curing time will reduce down time for mobile
assets representing significant cost savings to owners.
Peptide Technologies has developed proven products that have successfully
integrated fouling prevention with environmental safety with fouling prevention
in the aquatic ecosystem. All of the coatings simply prevent the attachment of
fouling organisms and does not affect the welfare of other aquatic life. Indeed,
our coatings have been applied to oyster shells to prevent fouling and
subsequently shown not to affect the well-being of the animal. One of our
products, AquaCrete Natural coating has also been shown to be also effective
outside the aquatic environment in preventing algal attachment on concrete and
thereby prevent algal fouling of walk ways or buildings located in humid or
moist environments.
Peptide Technologies coatings offer a unique solution to environmental fouling
for a variety of substrates. The coatings effectiveness, ease and speed of
application and its non-hazardous nature will ensure the protections of
industrial assets and as well be compliant with environmental legislation.
Our patent-protected fouling prevention coatings (AquaNatural Industrial,
AquaCrete Natural, AquaCulture Natural, AquaNatural Marine) are based on
proprietary organic formulations developed over the past 18 years. After the
past two years of conclusive product testing and formula improvements, we have
27
launched a perfected product line offering the industry safe and sustainable
fouling prevention coatings used to combat the rapidly growing problems caused
by the attachment of hard fouling agents in the marine and fresh water
environments. Our paint is unique globally and represents the ultimate in a
green approach to fouling of mobile and fixed assets.
OUR ADVANTAGES
(a) The products are an Earth friendly organic solution and non-hazardous
to aquatic life;
(b) They can be applied to both stationary and moving substrates;
(c) All of our coatings have a Quick 30 minute cure time;
(d) Our products have been proven to be effective in both fresh and marine
waters;
(e) Our coatings can be applied as a paint or spray;
(f) We offer several COLOR options to suit the end-users application; as
well as a completely CLEAR coating, and,
(g) Our non-dangerous and non-hazardous coatings work by simply preventing
attachment by hard fouling agents and bio-film without harming aquatic
life
OUR OUTLOOK
-----------
The International Marine coatings market currently generates revenues of $5
Billion annually and is projected to reach $10 Billion within 4 years according
to Frost & Sullivan. Several factors will lead to the doubling of the global
market in such a short time frame. Such factors include the introduction of an
eco-friendly solution such as Peptide Technologies' products. The availability
of these products will facilitate painting of the ships and marine assets
globally and not just in traditional unregulated shipping zones. Peptide
Technologies is positioned to provide the entire marine coatings industry with
several solutions to meet the change in environmental regulations, reduction in
fuel consumption and lowering dry dock costs with its innovative product line.
Our commitment to the Earth and Oceanic sustainability will drive our growth to
enable a new generation of fouling prevention coatings.
Background
Bio-Fouling
-----------
Bio-fouling is the development of organic layers, created by the settlement of
organisms and their metabolic products (primarily caused by a variety of
organisms including: bacteria, algae and hard agents (mussels, barnacles etc.)).
Fouling produces several problems for equipment and aquatic structures,
deteriorating their performance and limiting their useful life.
Typically fouling begins with the formation of bio-films which develop and
affect the interaction between the substrate surface and the environment. In
most instances, bio-film developments compromise the substrate's integrity and
facilitate the subsequent production of algal growth and the attachment of other
hard agents.
Bio-films are predominately aggregates of bacterial cells, which attach to and
grow on a substrate, which are often resistant to disinfection. Bacterial
bio-films cause serious problems for industrial fluid processing operations
including: mechanical blockage interference in heat transfer process and
microbial-induced corrosion. In engineered systems such as cooling water
systems, food processing and other industrial applications, bio-film is a risk
to public health. Product spoilage and souring are consequences of
bio-film-mediated contamination.
Overall, bio-fouling represents a significant economic cost to a variety of
man-made structures and facilities including: desalination plants, piers, and
pylons, buoys, boilers, steam generators, cooling towers, evaporators,
distillation units, heat exchangers, engine jackets and valves. In addition,
bio-fouling generally increases fuel consumption, reduces efficiency, and
greatly increases corrosion rates.
AquaNatural Industrial, AquaCrete Natural, AquaCulture Natural and AquaNatural
Marine products are the only non-hazardous, non-toxic, safe, user-friendly,
fouling prevention coatings. These four products prevent bio-film adherence and
28
subsequent attachment by other hard fouling agents. Our Fouling Prevention
coatings are the only four environmentally-safe paints for preventing the
attachment of bio-films and hard fouling agents.
Other key attributes of our four fouling prevention, products include:
o Our protective coating paints are available in several colors
including white and clear;
o Our products do not kill fouling agents, simply prevent them from
attaching to our coated surfaces;
o Our products can be applied to netting material, rope, fiberglass,
cement and a variety of metal substrates; and,
o Of all the registered anti-fouling paints, Peptide Technologies,
Inc.'s fouling prevention coatings are the only coatings registered
non-hazardous, non-toxic paint coatings, and therefore rated as
non-dangerous goods.
Zebra and Quagga Mussels
------------------------
The zebra mussel (Dreissena polymorpha) and its cousin, the quagga mussel
(Dreissena rostriformis bugensis), are small bivalve mollusks with two matching
half shells, having an average life span of 3 to 5 years. Zebra mussels are
native to the Black, Caspian, and Azov Seas, dating back to 1769. By the late
18th and early 19th centuries, zebra mussels had spread to most all major
drainages of Europe because of widespread construction of canal systems. They
first appeared in Great Britain in 1824, where they are now well established.
Since then, zebra mussels have expanded their range into Denmark, Sweden,
Finland, Ireland, Italy, and the rest of Western Europe. Zebra mussels were
first discovered in North America in 1988 in the Great Lakes. The first account
of an established population came from Canadian waters of Lake St. Clair, a
water body connecting Lake Huron and Lake Erie. By 1990, zebra mussels had been
found in all the Great Lakes. The following year, zebra mussels escaped the
Great Lakes basin and found their way into the Illinois and Hudson rivers. The
Illinois River was the key to their introduction into the Mississippi River
drainage which covers over 1.2 million square miles. Since its introduction, the
zebra mussel has spread to 23 states in America and two Canadian provinces.
The quagga mussel is indigenous to the Dneiper River drainage of Ukraine and
Ponto-Caspian Sea. It was discovered in the Bug River in 1890 by Andrusov, who
named the species in 1897. The quagga mussel was first sighted in the Great
Lakes in September 1989, when one was found near Port Colborne, Lake Erie,
though the recognition of the quagga type as a distinct species was not until
1991. In August 1991, a mussel with a different genotype was found in a random
zebra mussel sample from the Erie Canal near Palmyra, New York, and after
confirmation that this mussel was not a variety of Dreissena polymorpha, the new
species was named "quagga mussel" after the "quagga", an extinct African
relative of the zebra. The first sighting of quagga mussels outside the Great
Lakes basin was made in the Mississippi River between St. Louis, Missouri and
Alton, Illinois in 1995. In January 2007, populations of quagga mussels were
discovered in Lake Mead near Boulder City, Nevada, and in Lake Havasu and Lake
Mohave on the California/Arizona border.
The quagga mussel is a prolific breeder, possibly contributing to its spread and
abundance. Dreissena are dioecious (either male or female) with external
fertilization. A fully mature female mussel is capable of producing up to one
million eggs per year. After fertilization, pelagic microscopic larvae, or
veligers, develop within a few days and these veligers soon acquire minute
bivalve shells. Free-swimming veligers drift with the currents for three to four
weeks feeding by their hair-like cilia while trying to locate suitable substrata
to settle and secure byssal threads. Zebra and quagga mussels accumulate organic
pollutants within their tissues to levels more than 300,000 times greater than
concentrations in the environment and these pollutants are found in their
pseudofeces, which can be passed up the food chain, therefore increasing
wildlife exposure to organic pollutants (Snyder et al., 1997). Another major
threat involves the fouling of native freshwater mussels. Since quaggas were
discovered in Lake Michigan in 1998, plankton rings formed by the passage of
storms have been eaten away by the quagga mussels, threatening the local
ecosystem.
Numerous pipelines, filter screens, hydroelectric turbines and pumping stations,
irrigation tunnels, canals and aqueducts are becoming clogged with quagga and
zebra mussels, and this proliferation and dispersion of mussel populations
threatens to impact reclamation operations and multiple dams across North
America, resulting in the interruption of hydropower and water delivery at
significant economic costs. Of particular concern is the blockage of water lines
designed to cool the hydropower turbines at dams like Hoover.
The quagga mussels, which grow to about 1.5 inches, are clogging water lines
that are used to cool the 17 massive hydropower turbines at Hoover Dam and have
29
already forced dam operators to temporarily shut down turbines that supply
electricity to 1.6 million people in southern Nevada, Arizona and California.
The mussels have caused similar problems at the downstream Davis Dam in Lake
Mohave and Parker Dam in Lake Havasu, both of which provide electricity for
thousands of people in Arizona and California. The mussels have also threatened
to clog water intake lines in Lake Mead operated by the Southern Nevada Water
System that supply water to more than 2 million people in the Las Vegas area.
What took decades to unfold in the Great Lakes has played out in a matter of
months in Lake Mead. Quaggas can lay eggs six or seven times a year in the
warmer water, compared with once or twice a year in the Great Lakes.
If you drained Lake Mead above Hoover Dam, says National Park Service biologist
Bryan Moore, it would reveal that brown canyon walls that were mussel-free just
two years ago are now black with quaggas at densities of up to 55,000 per square
meter. The Bureau of Reclamation, which operates the Hoover, Davis and Parker
dams, has employed divers with high-pressure water hoses to blow mussels out of
pipelines and filter gates, and the agency retains the option of using chlorine
treatments on the mussels if necessary. But those treatments are expensive,
temporary and, in the case of chlorine, can have negative environmental effects.
Colonization of the Columbia River Basin (CRB)in the Pacific Northwest by zebra
and quagga mussel could affect all submerged components and conduits of the
Federal Columbia River Power System (FCRPS) including trash racks, raw water
distribution systems (headers), turbine bearing cooling systems, diffuser
plates, service and fire-water systems, and fish passage facilities.
Despite the uncertainty about zebra and quagga mussel tolerance to water
velocity, irregularities such as cracks and crevices and scaling in older pipes
and flanges can provide lower velocity refugia where zebra and quagga mussel
settlement can occur. The attached mussels, in turn, then produce additional low
flow refuges, allowing colonization in otherwise inhospitable flow environments.
Settlement can also occur when water flow is reduced during generation down-time
as conditions become more conducive to attachment.
Zebra and quagga mussel densities within the CRB could vary widely depending on
water chemistry, food availability, and breeding population. After their initial
introduction, zebra mussel populations can rapidly increase by orders of
magnitude, and then similarly decrease. Under ideal conditions in the Laurentian
Great Lakes zebra mussel densities reach 700,000 - 800,000 per square meter
(Kovalak et al, 1993). In the lower Mississippi River, where the zebra mussel
has been introduced, densities of 400,000 per square meter have been reported
(Kraft, 1995). The Mississippi has an ideal environment for zebra and quagga
mussels, in part because food resources are abundant (Kraft, 1995). While
Columbia River water quality parameters are favorable to zebra and quagga mussel
colonization (Athearn 1999), the Columbia River's lower plankton densities in
comparison to the Mississippi or Great Lakes, may limit zebra and quagga mussel
population densities.
Densities of zebra and quagga mussels in the Pacific Northwest will determine
the severity of impacts on hydropower, navigation, and fish passage facilities.
Zebra mussel densities in powerhouses will depend on the configuration of the
water systems and water conduit materials. The potential economic impacts of
zebra and quagga mussels on hydropower generation facilities in the Columbia
River will be determined by a number of factors including density, growth rate,
and maintenance costs. While density and growth are affected by environmental
factors as noted above, maintenance costs will also be driven by the difficulty
in accessing fouled areas, the methods available for removal and control, and
the amount of time available for maintenance activities. They prefer to cling to
flat, stainless steel structures where water flows less than 6 feet per second.
The muscles infestation sets in and begins to clog hydroelectric power cooling
pipes and other hardware in the dams' operations with quagga colonies. Not only
do they pose a threat to the cooling pipe system for hydroelectric turbines, but
also to the network that supplies domestic water for workers and visitors at the
dams.
Economic Impacts
o Hydroelectric Dams and Nuclear Power Plants
There are more than 85,000 dams in the United States alone, of which
approximately 11% are federally owned and operated. The major concern is the
30
blockage of water lines designed to cool the hydropower turbines at dams like
Hoover. This problem has already caused a "significant increase in the frequency
of high temperature alarms in cooling systems, requiring shutdowns" so that the
mussels could be removed.
Quagga
The quagga mussels, which grow to about 1.5 inches, are clogging water lines
that are used to cool the 17 massive hydropower turbines at Hoover Dam and have
already forced dam operators to temporarily shut down turbines that supply
electricity to 1.6 million people in southern Nevada, Arizona and California.
The mussels have caused similar problems at the downstream Davis Dam in Lake
Mohave and Parker Dam in Lake Havasu, both of which provide electricity for
thousands of people in Arizona and California. The mussels have also threatened
to clog water intake lines in Lake Mead operated by the Southern Nevada Water
System that supply water to more than 2 million people in the Las Vegas area.
Maintenance costs will also be driven by the difficulty in accessing fouled
areas, the methods available for removal and control, and the amount of time
available for maintenance activities. It has been estimated that hundreds of
millions of dollars is spent annually to combat the mussel infestation at
hydroelectric dams alone, and it is expected that this amount will increase
exponentially once the infestation has spread to the West.
Virtually any submerged area with a moderate flow rate that draws water from an
infested water source is vulnerable to colonization. This is especially true of
areas that offer protection to small mussels, such as crevices or seams. Intake
screens, for example, are common settlement areas and are often coated with
clumps or druses of mussels. The presence of dislodged shells in the discharge
of a facility's raw well or forbay is a common first indicator of the presence
of zebra mussels in the raw water main. Facilities may also experience a
noticeable decrease in head pressure. Most facilities have numerous components
subject to severe bio-fouling,
o Shipping Industry
The shipping industry worldwide spends huge amounts every year combating the
effects of "fouling". Every year or two, ocean going vessels must dry-dock in
order to undergo extensive work over two or more weeks to remove barnacles that
have attached to the hull. Prior to dry-docking, ships gradually undergo rapid
increases in additional fuel costs due to increased drag from fouling. The
mechanism involved in fouling occurs in a series of three steps. Within one
week, the hull surface is coated with a slimy deposit. Following this, various
micro-organisms (bacteria) attach. Barnacles attach to this slimy/bacterial
coating and become attached to the ship's hull using a bio-cement generated by a
series of three proteins that undergo a conformational change, within the
organism. This cement is one of, if not the strongest cement known to date of
anything produced naturally.
The current anti-fouling paint applied to ship hulls contains toxic chemicals
and heavy metals. However, as the international shipping community has been
issuing legislation prohibiting the use of these environmentally hazardous
substances - the need for alternatives is pressing.
o Recreational Boating Industry
In contrast, Lake Mead Marina predicts the costs to the West's recreational
boating industry alone will be immense in the coming few years. Mussels are
smothering everything under the waterline at marinas, making simple maintenance
on boats and floating docks expensive and time consuming, not to mention
dangerous due to the razor-sharp shells being plucked from the water.
The United States Park Service, which figures the mussels have been in Lake Mead
since 2005, is trying to protect the rest of the West's waters by requiring
boats that have been docked in a slip to be decontaminated with jets of scalding
water before departing Lake Mead. A killer hot wash costs about $40 for a small
boat and up to $200 for a houseboat.
o Ecological Damage
The infestation of zebra and quagga mussels are wreaking havoc on the native
species indigenous to the waterways they inhabit. These mussels attach to other
mussel species and crustaceans making it almost impossible for them to eat and
survive. While the zebra and quagga do have predator enemies, there are not
enough to consume the rapidly growing infestation.
31
This is more than an ecological concern. The federal government plans to spend
over a billion dollars in the coming years to help these species recover, and
zebra and quagga mussels have a history of ravaging native species in the waters
they invade. In Lake Michigan, for example, prey fish numbers are less than 10%
of what they were before the invasive mussels arrived.
Zebra mussels are also believed to be the source of deadly avian botulism
poisoning that has killed tens of thousands of birds in the Great Lakes since
the late 1990s.
Zebra and quagga mussels accumulate organic pollutants within their tissues to
levels more than 300,000 times greater than concentrations in the environment
and these pollutants are found in their pseudofeces, which can be passed up the
food chain, therefore increasing wildlife exposure to organic pollutants.
Another major threat involves the fouling of native freshwater mussels. Since
quaggas were discovered in Lake Michigan in 1998, plankton rings formed by the
passage of storms have been eaten away by the quagga mussels, threatening the
local ecosystem.
Other zebra and quagga mussel infested applications include:
o Drinking water treatment facilities;
o Fish hatcheries and aquaculture facilities;
o Golf courses;
o Impoundments and reservoirs;
o Institutions (hospitals, colleges, etc.);
o National scenic river ways;
o Navigation locks;
o Public agencies; and
o Farm irrigation water.
Facilities and Properties
We do not own our own facilities and are presently renting an identity office in
Seattle, Washington.
Employees
Our officers, directors, and employees are responsible for planning, developing
and operational duties and will continue to do so throughout the early stages of
our growth.
Management's Discussion and Analysis of Financial Condition and Results of
Operations
Material Changes in Financial Condition
At February 28, 2014, our cash balance was $868. Cash on hand is currently our
only source of liquidity. We do not have any lending arrangements in place with
banking or financial institutions and we do not anticipate that we will be able
to secure these funding arrangements in the near future.
At February 28, 2014, we had a working capital deficit of $1,911,849 compared to
a working capital deficit of $1,750,965 at November 30, 2013. At February 28,
2014, our total assets consisted of cash of $868, a website with a net carrying
value of $5,000, and intangible assets and intellectual property of $45,000.
This compares with total assets at November 30, 2013, which consisted of cash of
$157, a website with a net carrying value of $5,833 and intangible assets and
intellectual property of $45,000.
At February 28, 2014, our total current liabilities increased to $1,912,717 from
$1,751,122 at November 30, 2013. During the three months ended February 28,
2014, accounts payable and accrued liabilities increased by $164,420.
We believe our existing cash balances will not be sufficient to carry our normal
operations over the next three (3) months. Our short and long-term survival is
32
dependent on sales of securities as necessary or from shareholder loans, and
thus, to the extent that we require additional funds to support our operations
or the expansion of our business, we will attempt to sell additional equity
shares or issue debt. Any sale of additional equity securities will result in
dilution to our stockholders. Continuing events in worldwide capital markets may
make it more difficult for us to raise additional equity or capital. There can
be no assurance that additional financing, if required, will be available to us
or on acceptable terms.
Result of Operations
For The Three Months Ended February 28, 2014 Compared To The Three Months Ended
February 28, 2013.
We recognized nil revenues from operational sales during the three months ending
February 28, 2014.
During the three months ended February 28, 2014, operating expenses were
$174,542 compared to $244,573 for the three months ended February 28, 2013. The
decrease of $70,031 was due to a decrease in consulting fees of $75,000 due to
the mutual termination of that contract on November 30, 2013; and an increase in
supplies expense of $7,782 required for product testing. Operating expenses
during the three months ended February 28, 2014, consisted of salaries expense
of $157,940, professional fees of $5,750, general and administrative expenses of
$3,070, and supplies and materials expense of $7,782 compared to salaries
expense of $159,000, consulting fees of $75,000, professional fees of $8,633,
and general and administration fees of $1,940 incurred for the three months
ended February 28, 2013.
We recognized a net loss of $171,717 for the three months ended February 28,
2014, compared to a net loss of $244,364 for the three months ended February 28,
2013.
Off-Balance Sheet Arrangements
We currently do not have any off-balance sheet arrangements.
Critical Accounting Policies and Estimates
The preparation of the Company's interim consolidated financial statements in
conformity with generally accepted accounting principles in the United States
requires management to make assumptions and estimates that affect the reported
amounts of assets, liabilities, revenues and expenses as well as the disclosure
of contingent assets and liabilities at the date of the interim consolidated
financial statements and the reported amounts of revenues and expenses during
the reporting period. The following is a summary of the significant accounting
policies and related estimates that affect the Company's financial disclosures:
Principles of Consolidation
These interim consolidated financial statements include the accounts of the
Company and its wholly-owned subsidiary Pept Peptide Technologies, Inc., a
company incorporated in the province of British Columbia on August 5, 2013.
All significant inter-company balances and transactions have been eliminated
upon consolidation.
Organizational and Start-up Costs
Costs of start-up activities, including organizational costs, are expensed as
incurred in accordance with Accounting Standards Codification ("ASC") 720-15,
"Start-Up Costs".
Development-Stage Company
During the year ended November 30, 2010, the Company abandoned its previous
business of sale of original artwork and re-entered the development stage with
its intended new business, which currently has no revenues. Management expects
33
to sustain losses from operations until such time it can generate sufficient
revenues to meet its anticipated cost structure. The Company is considered a
development-stage company in accordance with the ASC 915, "Accounting and
Reporting by Development-Stage Enterprises". A development-stage enterprise is
one in which planned principal operations have not commenced or if its
operations have commenced, there has been no significant revenues there from.
Cash and Cash Equivalents
Cash and cash equivalents include highly liquid investments with original
maturities of three months or less.
Website
In accordance with ASC 350-50, "Website Development Costs", expenditures during
the planning and operating stages of the Company's website are expensed as
incurred. Expenditures incurred during the website application and
infrastructure development stage are capitalized and amortized to expense over
the website's estimated useful life of 3 years.
Intangible Assets
Intangible assets include the cost of acquiring the intellectual property. In
accordance with ASC 350-30 "General Intangibles Other Than Goodwill", an
intangible asset that is acquired either individually or with a group of other
assets shall be recognized. Costs of internally developing, maintaining, or
restoring intangible assets that are not specifically identifiable, that have
indeterminate lives, or that are inherent in a continuing business and related
to an entity as whole, shall be recognized as an expense when incurred. The
intellectual property is determined to have an indefinite useful life and is not
subject to amortization. The useful lives of intangible assets are reassessed at
each reporting period.
Impairment of Long-Lived Assets
Long-lived assets include the website and intangible assets and intellectual
property. Long-lived assets subject to amortization are reviewed for impairment
whenever events or changes in circumstances indicate that the carrying amount of
an asset may not be recoverable. Long-lived assets not subject to amortization
are tested for impairment annually or more frequently if events or changes in
circumstances indicate that the asset might be impaired. Recoverability of
assets to be held and used is measured by a comparison of the carrying amount of
an asset to the estimated undiscounted future cash flows expected to be
generated by the asset. If the carrying amount of an asset exceeds its estimated
future cash flows, an impairment charge is recognized as the amount by which the
carrying amount of the asset exceeds the fair value of the asset. There has been
no impairment as of February 28, 2014.
Research and Development
Research and development expenses are charged to operations as incurred.
Income Taxes
The Company adopted the ASC 740, "Accounting for Income Taxes". ASC 740 requires
the use of the asset and liability method of accounting of income taxes. Under
the asset and liability method of ASC 740, deferred tax assets and liabilities
are recognized for the future tax consequences attributable to temporary
differences between the interim consolidated financial statements carrying
amounts of existing assets and liabilities and their respective tax bases.
Deferred tax assets and liabilities are measured using enacted tax rates
expected to apply to taxable income in the years in which those temporary
differences are expected to be recovered or settled. A valuation allowance is
established when necessary to reduce deferred tax assets to the amount expected
to be realized.
Basic and Diluted Income (Loss) per Share
In accordance with ASC 260, "Earnings per Share", the basic loss per common
share is computed by dividing net loss available to common stockholders by the
weighted average number of common shares outstanding. Diluted loss per common
share is computed similar to basic loss per common share except that the
denominator is increased to include the number of additional common shares that
would have been outstanding if the potential common shares had been issued and
34
if the additional common shares were dilutive. Diluted earnings per share are
not shown for periods in which the Company incurs a loss because it would be
anti-dilutive. At February 28, 2014, the Company had no stock equivalents that
were anti-dilutive and excluded in the earnings per share computation.
Estimated fair value of financial instruments
The carrying value of the Company's interim consolidated financial instruments,
consisting of cash, accounts payable, and notes payable approximate their fair
value due to the short-term maturity of these instruments. Unless otherwise
noted, it is management's opinion that the Company is not exposed to significant
interest or currency risks arising from these financial statements.
Financial instruments that potentially subject the Company to concentrations of
credit risk consist principally of cash and cash equivalents. At February 28,
2014, all cash and cash equivalents were insured by agencies of the U.S.
Government.
Foreign Currency Translation
The interim consolidated financial statements are presented in U.S. dollars. In
accordance with ASC 830 "Foreign Currency Matters", foreign denominated monetary
assets and liabilities are translated to their U.S. dollar equivalents using
foreign exchange rates which prevailed at the balance sheet date. Revenue and
expenses are translated at average rates of exchange during the period. Related
translation adjustments are reported as a separate component of stockholders'
equity, whereas gains or losses resulting from foreign currency transactions are
included in results of operations.
Comprehensive Income (Loss)
The Company adopted ASC 220, "Reporting Comprehensive Income". ASC 220 requires
that the components and total amounts of comprehensive income be displayed in
the interim consolidated financial statements beginning in 1998. Comprehensive
income includes net income and all changes in equity during a period that arises
from non-owner sources, such as foreign currency items and unrealized gains and
losses on certain investments in equity securities.
Use of Estimates
The preparation of the Company's interim consolidated financial statements are
in conformity with U.S. GAAP which requires management to make estimates and
assumptions that affect the amounts reported in these consolidated financial
statements and accompanying notes. Actual results could differ from those
estimates.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We believe our market risk exposures arise primarily from exposures to
fluctuations in interest rates and exchange rates. We presently only transact
business in Canadian and U.S. Dollars. We believe that the exchange rate risk
surrounding the future transactions of the Company will not materially or
adversely affect our future earnings. We do not believe that we are subject to
any seasonal trends. We do not use derivative financial instruments to manage
risks or for speculative or trading purposes.
ITEM 4. CONTROLS AND PROCEDURES
As of the end of the period covered by this report, we conducted an evaluation,
under the supervision and with the participation of our Chief Financial Officer,
of our disclosure controls and procedures (as defined in Rules 13a-15(e) and
15d-15(e) under the 1934 Act). Based on this evaluation, the Chief Financial
Officer concluded that our disclosure controls and procedures are effective to
ensure that information required to be disclosed by us in reports that we file
or submit under the 1934 Act is recorded, processed, summarized and reported
within the time periods specified in the Securities and Exchange Commission
rules and forms.
35
Our management is responsible for establishing and maintaining adequate internal
control over financial reporting for the company in accordance with as defined
in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control
over financial reporting is designed to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted
accounting principles.
Management's assessment of the effectiveness of the small business issuer's
internal control over financial reporting is as of the quarter ended February
28, 2014.
Because of its inherent limitations, internal control over financial reporting
may not prevent or detect misstatements. Also, projections of any evaluation of
effectiveness to future periods are subject to the risk that controls may become
inadequate because of changes in conditions, or that the degree of compliance
with the policies or procedures may deteriorate.
There was no change in our internal control over financial reporting that
occurred during the fiscal quarter ended February 28, 2014, that has materially
affected, or is reasonably likely to materially affect, our internal control
over financial reporting.
PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
None.
ITEM 1A. RISK FACTORS
Not applicable.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
None.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. MINE SAFETY DISCLOSURE
Not Applicable.
ITEM 5. OTHER INFORMATION
None
ITEM 6. EXHIBITS
Exhibit
Number Description
31.1 Section 302 Certification - Chief Executive Officer.
31.2 Section 302 Certification - Chief Financial Officer.
32.1 Certification Pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of
2002 - Chief Executive Officer.
32.2 Certification Pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of
2002 - Chief Financial Officer.
36
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized, on this 8th day of April,
2014.
PEPTIDE TECHNOLOGIES, INC.
Date: April 8, 2014 By: /s/ Scott McKinley
------------------
Name: Scott McKinley
Title: Chief Executive Officer
Date: April 8, 2014 By: /s/ Erik Odeen
--------------
Name: Erik Odeen
Title: Chief Financial Officer
3
